Holen Sie sich die Stockscreener-App
9.85
3.90%
-0.40
Handel nachbörslich:
9.99
0.14
+1.42%
Schlusskurs vom Vortag:
$10.25
Offen:
$10.27
24-Stunden-Volumen:
1.46M
Relative Volume:
0.87
Marktkapitalisierung:
$854.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-4.5392
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+2.93%
1M Leistung:
+20.56%
6M Leistung:
+74.96%
1J Leistung:
-46.00%
1-Tages-Spanne:
$9.70
$10.27
1-Wochen-Bereich:
$9.42
$10.41
52-Wochen-Spanne:
$5.41
$19.73
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.85 | 889.67M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Identifying reversal signals in Kura Oncology Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Custom strategy builders for tracking Kura Oncology Inc.2025 Trade Ideas & Fast Gain Stock Tips - newser.com
Will Kura Oncology Inc. stock reach all time highs in 2025Exit Point & Weekly Watchlist for Hot Stocks - newser.com
Kura Oncology (NASDAQ:KURA) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Advanced analytics toolkit walkthrough for Kura Oncology Inc.Earnings Beat & High Accuracy Swing Trade Signals - newser.com
Kura Oncology (NASDAQ:KURA) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Kura Oncology Inc. recovery potential after sell offMarket Performance Summary & Verified Technical Signals - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
How Kura Oncology Inc. stock reacts to bond yieldsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
Real time social sentiment graph for Kura Oncology Inc.Weekly Investment Report & Verified Entry Point Signals - newser.com
Kura Oncology (NASDAQ:KURA) Trading 8.9% HigherStill a Buy? - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 35,779 Shares of Kura Oncology, Inc. $KURA - MarketBeat
What drives Kura Oncology Inc stock priceEarnings Growth Projections & High Yield Market Growth - earlytimes.in
Kura Oncology, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
What MACD signals say about Kura Oncology Inc.2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Can Kura Oncology Inc. stock withstand economic slowdownJuly 2025 WrapUp & Community Trade Idea Sharing Platform - newser.com
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
Kura Oncology Inc. stock prediction for this week2025 Support & Resistance & Fast Entry Momentum Alerts - newser.com
How Kura Oncology Inc. stock performs in rate cut cyclesWall Street Watch & Low Risk High Reward Ideas - newser.com
Will Kura Oncology Inc. bounce back from current supportGap Up & Smart Investment Allocation Insights - newser.com
Is Kura Oncology Inc a good long term investmentCash Flow Trends & View Live Stock Forecasts Instantly - earlytimes.in
Kura Oncology (KURA) Grants Inducement Awards to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
122,250-Option Grant for New Hires: Kura Oncology Grants Options at $9.20, vesting over four years - Stock Titan
How sustainable is Kura Oncology Inc. stock dividend payoutAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Applying chart zones and confluence areas to Kura Oncology Inc.Earnings Risk Report & High Yield Stock Recommendations - newser.com
Kura Oncology, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Kura Oncology at UBS Virtual Oncology Day: Strategic Advances in AML Treatment - Investing.com Canada
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia - MarketScreener
Kura Oncology (KURA) Advances KOMET-007 Trial with First Patient Dosed - GuruFocus
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology and Kyowa Kirin Initiate KOMET-007 Trial Evaluating Ziftomenib in Combination with FLT3 Inhibitors for Frontline Treatment of AML - Quiver Quantitative
Kura Oncology stock maintains Market Outperform rating at Citizens JMP By Investing.com - Investing.com Canada
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bair Teresa Brophy sells Kura Oncology (KURA) shares for $78,736 By Investing.com - Investing.com Australia
Kura Oncology stock in focus as first patient dosed in pivotal trial - Investing.com Canada
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Kura Oncology (KURA) Buy Recommendation - Nasdaq
Citizens JMP Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):